MDR Bacterial Infections Our Treatment Option

More documents

Recommendations

Info

Drug of Choice for ESBL-producingEnterobacteriaCommunity-acquired infection• cSSSI• Diabetic infected ulcer• cIAI• Pyelonephritis• CAP due to Klebsiella spp.• Primary bacteremiaCarbapenem• Ertapenem• Imipenem• Meropenem• Doripenem• Biapenem
Antimicrobial Selection according to Risk ofInfection due to ESBL-producing EnterobacteriaEmpiric antibiotics by De-escalation MethodNo/Low risk of ESBLCeftriaxoneCeftazidimeCefepimePiperacillin-tazoMod./High risk of ESBLCarbapenem:ertapenemimipenemmeropenemdoripenem+Netilmicin/amikacin/levofloxacin/ ciprofloxacin/ Fosfomycin
Page 1 and 2: MDR Bacterial Infections:Our Treatm
Page 5 and 6: IDSA News: 10 New Antibiotics by 20
Page 7 and 8: 60504030201001911102010719992000261
Page 9 and 10: Definition & Action of KPC, CRKP an
Page 11 and 12: Maria Souli, Irene Galani, Anastasi
Page 13 and 14: Antimicrobial Susceptibility for ND
Page 15 and 16: KPC-p K. pneumoniaeisolate. (USA)Ca
Page 18 and 19: MIC distributions of NDM-1 Enteroba
Page 22 and 23: Antimicrobial Option by Risk Level
Page 24 and 25: In vitro activities of fosfomycin a
Page 26 and 27: 0.5, 1.0, 2.0-gm Human Simulated Pr
Page 28 and 29: FIC Index & InterpretationInterpret
Page 30 and 31: FIC Index of MDR P. aeruginosaStrai
Page 32 and 33: Population PharmacokineticAnalysis
Page 34 and 35: Attenuation of Colistin Bactericida
Page 36 and 37: Pharmacokinetic/Pharmacodynamic Det
Page 38 and 39: Recommended Definite Therapy for Se
Page 40 and 41: Breakpoint Criteria of Vancomycin f
Page 42 and 43: One Gram bid: Enough for Vancomycin
Page 44 and 45: การใชยา vancomycin
Page 46 and 47: ยาขนานอื่น ถ
Page 48 and 49: Early Combination Rx vs. Monotherap
Page 54: Thank youAny Comment?Any Question?

MDR Bacterial Infections Our Treatment Option

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?